8 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $82M | -$66M | 0.0% | -93.0% | -30.7% | -24.3% | -$75M | — | $231M |
| 2024 | $152M | -$81M | 0.0% | -62.8% | -33.6% | -23.5% | -$60M | — | $237M |
| 2023 | $167M | -$30M | 0.0% | -46.9% | -10.7% | -6.9% | -$21M | — | $292M |
| 2022 | $206M | $9M | 0.0% | 5.9% | 3.5% | 2.1% | $24M | — | $392M |
| 2021 | $12M | -$204M | 0.0% | -1641.3% | -89.2% | -51.8% | -$138M | $15M | $370M |
| 2020 | $10M | -$72M | 0.0% | -749.8% | -18.2% | -15.1% | -$45M | $15M | $463M |
| 2019 | $21M | -$26M | 0.0% | -122.7% | -100.8% | -31.6% | -$7M | $15M | $71M |
| 2018 | $16M | -$22M | 0.0% | -138.5% | -159.7% | -49.3% | -$22M | $10M | $37M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $3M | -$24M | 0.0% | -863.3% | -13.8% | -10.6% | -$20M | — | $191M |
| Mar '26 | $2M | -$27M | 0.0% | -1403.7% | -14.1% | -11.0% | -$19M | — | $211M |
| Dec '25 | $7M | -$29M | 0.0% | -435.1% | -13.6% | -10.7% | -$16M | — | $231M |
| Sep '25 | $17M | -$13M | 0.0% | -96.3% | -6.0% | -4.8% | -$17M | — | $180M |
| Jun '25 | $28M | -$9M | 0.0% | -41.0% | -4.0% | -3.0% | -$6M | — | $196M |
| Mar '25 | $29M | -$14M | 0.0% | -57.3% | -6.0% | -4.2% | -$35M | $15M | $217M |
| Dec '24 | $23M | -$30M | 0.0% | -146.7% | -12.5% | -8.7% | -$284000 | — | $237M |
| Sep '24 | $42M | -$7M | 0.0% | -25.8% | -2.6% | -1.9% | -$24M | — | $237M |
| Jun '24 | $50M | -$17M | 0.0% | -42.4% | -6.7% | -4.4% | -$30M | — | $260M |
| Mar '24 | $38M | -$27M | 0.0% | -80.0% | -10.2% | -6.4% | -$6M | — | $288M |
| Dec '23 | $31M | -$12M | 0.0% | -59.2% | -4.2% | -2.7% | -$2M | — | $292M |
| Sep '23 | $45M | -$16M | 0.0% | -42.8% | -5.8% | -3.5% | -$33M | $20M | $312M |
| Jun '23 | $11M | -$53M | 0.0% | -526.4% | -18.4% | -12.2% | $50M | — | $323M |
| Mar '23 | $80M | $51M | 0.0% | 18.4% | 15.4% | 10.8% | -$37M | — | $328M |
| Dec '22 | $160M | $117M | 0.0% | 75.8% | 43.4% | 26.1% | $156M | — | $392M |
| Sep '22 | $13M | -$35M | 0.0% | -275.3% | -24.2% | -12.0% | -$45M | $13M | $238M |
| Jun '22 | $27M | -$22M | 0.0% | -81.5% | -12.6% | -6.4% | -$36M | $15M | $283M |
| Mar '22 | $5M | -$51M | 0.0% | -960.7% | -27.7% | -15.0% | -$51M | $15M | $320M |
| Dec '21 | $6M | -$39M | 0.0% | -649.7% | -16.9% | -9.8% | -$44M | $15M | $370M |
| Sep '21 | $2M | -$54M | 0.0% | -2208.5% | -20.9% | -12.4% | -$18M | $15M | $414M |
How the market has priced ARCT against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Arcturus Therapeutics Holdings Inc.'s revenue has grown 53.8% per year. These are computed facts, not advice.
As of FY2025, Arcturus Therapeutics Holdings Inc. reported — of total debt against $231M of cash.
In FY2025, gross margin was —, operating margin -93.0%, and net margin -80.2%.
As of Sep '26, Arcturus Therapeutics Holdings Inc. traded at a price-to-earnings ratio of about 95.9× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.